Cathy Perry

Cathy Perry is an experienced professional in clinical development and leadership within the biopharmaceutical industry. Currently serving as a Team Leader at Genentech since 2020, Cathy is engaged in foundational aspects of a new field. Previously, from 2017 to 2019, Cathy played a significant role in Merck's leadership team, spearheading the implementation of histopathology-based technologies across various therapeutic areas such as diabetes and oncology. As Director of Clinical Development at Portola Pharmaceuticals from 2015 to 2017, Cathy oversaw the development of a P2Y12 inhibitor for acute coronary syndrome. Additionally, Cathy's earlier tenure at CV Therapeutics from 2011 to 2014 involved leading the global Phase 2 and Phase 3 development of Regadenoson, which received U.S. approval. Cathy holds a Master's degree in Molecular and Cellular Biology from the University of North Carolina at Chapel Hill.